The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer.
The transforming growth factors beta are a family of peptides which are involved in the regulation of cell growth and differentiation. It has been suggested that the loss of sensitivity to growth inhibition by endogenous TGF-beta may contribute to the process of carcinogenesis in epithelial systems. However, many breast cancer cells remain sensitive to the growth inhibitory effects of these peptides, suggesting that the local induction of TGF-beta could provide a pharmacological approach to chemoprevention. Triphenylethylene anti-oestrogens, synthetic progestins and retinoids all offer potential as chemopreventative agents. A common feature of their mechanism of action is the ability to locally increase the production of the transforming growth factors beta.
Dickens
T A
TA
Hartwell Laboratory, Royal Marsden Hospital, London, UK.
Colletta
A A
AA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D006801:Humans; D011372:Progestins / Q000627:therapeutic use; D012176:Retinoids / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000096:biosynthesis*
D000970:Antineoplastic Agents; D011372:Progestins; D012176:Retinoids; D016212:Transforming Growth Factor beta; D013629:Tamoxifen